| abstract |
REFERS TO COMPOUNDS DERIVED FROM PYRROLIDINE OF FORMULA (I) WHERE R1 IS CYCLOALKYL (C3-C6) OR PHENYL OPTIONALLY SUBSTITUTED WITH F, Cl, CN, ALKYL (C1-C4), AMONG OTHERS; X IS A LINK, NH U O; Z IS COOR2, CONHSO2R3 OR CN, WHERE R2 IS H OR ALKYL (C1-C6) OPTIONALLY SUBSTITUTED WITH F; R3 IS ALKYL (C1-C6) OPTIONALLY SUBSTITUTED WITH F; Ar IS AN AROMATIC GROUP OF 1 TO 3 RINGS WHICH ARE PHENYL OR A HETEROAROMATIC RING OF 5 OR 6 MEMBERS OPTIONALLY SUBSTITUTED WITH F, CN, OH, ALKYLTIO (C1-C6), AMONG OTHERS. PREFERRED COMPOUNDS ARE: 3 - {[(4'-CYANOBIPHENYL-4-IL) OXY] METHYL} -1- (4-FLUOROBENZOYL) PYRROLIDIN-3-CARBOXYL; 3 - {[(4'-CYANOBIPHENYL-4-IL) OXY] METHYL} -1- (4-METOXYBENZOYL) PYRROLIDIN-3-CARBOXYL; 3 - {[4- (5-CHLOROPYRIMIDIN-2-IL) PHENOXY] METHYL} -1- (4-FLUOROBENZOYL) PYRROLIDIN-3-CARBOXYL ACID; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE ANTAGONISTS OF THE RECEPTOR-2 OF PROSTAGLANDIN E2 (PGE2) OR EP2 WITH SELECTIVITY AGAINST DP1 AND EP4, BEING USEFUL IN THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, ADENOMIOSIS, POLYCHISTIC OVARY SYNDROME |